34(2): 154-156. DOI: 10.1038/ng1161. [2]Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51. DOI: 10.1056/NEJMoa160...
2、BPS Bioscience. Cholesterol & the PCSK9 Pathway. 3、Christie M. Ballantyne et.al, Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616, JACC VOL. 81, NO. 16, 2023.
健康人群中给予单剂量的依洛尤单抗140mg或420mgs.c.后,LDL-C分别在14天和21天达到最低值(图4);健康人群中给予多剂量的依洛尤单抗140mg或420mgs.c.,达稳态后,LDL-C分别在给药后7天和14天达到最低值。 图4. 来源:ClinicalPharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharm...
4. Ballantyne, C. M. et al. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial. J Am Coll Cardiol. Mar 06, 2023. Epublished DOI: 10.1016/j.jacc.2023.02.018 5. Goldstein, J. L. et al. The LDL Receptor. Arteriosclerosis, Thrombosis, ...
[2]Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51. DOI: 10.1056/NEJMoa1609243. [3]Han Y, Chen J, Chopra VK, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high ca...
2. https://www.businesswire.com/news/home/20230306005288/en/Merck%E2%80%99s-MK-0616-an-Investigational-Oral-PCSK9-Inhibitor-Significantly-Reduced-LDL-C-in-Patients-with-Hypercholesterolemia-in-Phase-2b-Study?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork 3. https://www.jacc...
[2]Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51. DOI: 10.1056/NEJMoa1609243. [3]Han Y, Chen J, Chopra VK, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high ca...
8. Merck’s MK-0616 may become the first oral PCSK9 inhibitor in the dyslipidemia market. Clinical Trials Arena. 09, 03, 2023. 9. Grundy, S. M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC /NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summar...
[9]. 2024 ESC—Very short-term effects of single dose of proprotein convertase subtilisin kexin 9 inhibitor therapy before percutaneous coronary intervention. [10]. 2024 ESC—Inclisiran-containing low-density lipoprotein cholesterol reduction effectively stabilizes atherosclerotic plaques....
[4] Parhofer K G, et al. 3-year Clinical Outcomes Of Patients With Very High Cardiovascular Risk Eligible For Pcsk9 Inhibitor Treatment: Peri-dys Study[J]. EAS, 2024. [5] Galema A M H, et al. Efficacy and saf...